In the current debate about reform of the housing finance market, proponents of a continuing government role frequently argue that without government backing, the so-called "to be announced" (TBA) market could not exist. But that's simply not true.

Successfully translating scientific discoveries requires a sense of urgency, which some disease foundations seem to have, and many big pharmas appear to need. Patients waiting expectantly for medical research to produce important new cures are finding bad news almost everywhere they turn.

Every day patients receive treatments that do not work properly. For many this means no relief from symptoms, but for some death is the result. Yet concerted action against such products is limited. Before we can discuss why that's the case, I will attempt to explain what kind of products don’t work, and what we should call them.

The evolution of the European Union"s approach to regulating biosimilars is a potential model upon which we can design a process that facilitates access to biosimilars while providing assurances of safety.

Borrowers should be better educated and better equipped when signing on a mortgage loan.

In less than twenty-five years, government “affordable housing” and other housing policies have turned a healthy market into a financial ruin. Until Fannie and Freddie’s market dominance and the government’s role in the housing finance system are substantially reduced or eliminated, the United States will continue to have an inferior and unstable housing market.

President Obama's new defense strategy champions the same arguments military downsizers have invoked since 1991: The United States must invest in technology and disinvest in active-duty military personnel.

Many aid groups who purchase generic drugs for developing countries do not require evidence of bioequivalence.